Our Newsletter


The Story Behind Latisse Eyelash Growth Treatment

Posted on 18th Aug 2010 @ 2:41 PM

 

In 2001, Allergan – a leader in eye care, medical aesthetics and dermatology – was focused on creating a medicated eye drop to treat ocular hypertension. Ocular hypertension refers to a case in which the pressure inside the eyes is greater than normal. Allergan’s product successfully achieved the Company’s goal of lowering patients’ eye pressure. However, in the process many patients using the eye drops noted an interesting side effect – they started growing fuller, darker and longer eye lashes.

As a result of this side effect, Allergan took a more detailed look into the medication’s active ingredient – bimatoprost ophthalmic solution 0.03% - examining how it could generate lash growth. Based on the information Allergan obtained from this examination they conducted a clinical trial on efficacy and safety of the product for four months on 278 patients. The trial was a success and Latisse was approved by the FDA in December 2008 becoming the first and only FDA-approved prescription for inadequate eyelashes. It promotes longer, fuller and darker eyelashes.

Since that time approximately 1.5 million bottles of the Latisse Eyelash Growth Treatment solution have been sold. It is used by a number of celebrities including Brooke Shields and Claire Danes.

Of course, every patient is different so individual results may vary and as with any product you should check with your family physician before using it and be aware of and prepared for potential side effects.